Answers are grounded in this paper and cite their sources.
Currently, regular histopathology and immunohistochemistry are commonly taken for granted in the diagnosis of Cutaneous Malignant Melanoma (CMM).In addition, attempts at molecular diagnosis in dermatopathology have benefited from advances in pathobiology genomics and proteomics.They provide utmost information for optimal patient care.Sensitive techniques detect specific DNA and RNA sequences, and molecular methods were refined in the field of polypeptides.This review aims at covering on an overall glance about molecular genetics available as diagnostic supports in CMM.Laboratory methods have disclosed and highlighted some pathogenic pathways of atypical melanocytic neoplasms with particular emphasis on the activation of the Mitogen-Activated Protein Kinase (MAPK) signalling pathway (including BRAF and KIT) during the initiation step of the neoplasms.Many familial CMM contain mutations of the tumor suppressor gene p16 or CDKN2A.In addition, mutations in p53 are found in distinct CMM types.Many CMM are likely related to a variety of common low penetrance genes.Molecular dermatopathology represents a promising tool for both research and diagnosis.Knowledge of tumor mutation status is becoming increasingly important.The expected benefit of molecular dermatopathology tends to ultimately improve the targeted patient management.Such method evolution points to a need for improving the routine training requirements for dermatopathologists involved in cancer diagnostic responsibilities.
No takes yet. Share an insight, caveat, or question.
Gérald Pierard (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: